Two-year clinical outcome in patients with small coronary artery disease treated with everolimus- versus paclitaxel-eluting stenting.

[1]  P. Serruys,et al.  Impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 16 randomized trials. , 2014, Journal of cardiology.

[2]  K. Nasu,et al.  Difference of vascular response between everolimus- and paclitaxel-eluting stents for small coronary artery disease: Optical coherence tomography analysis☆☆☆★ , 2014, International journal of cardiology. Heart & vessels.

[3]  C. Siu,et al.  Angiographic and clinical outcomes of everolimus-eluting stent in the treatment of extra long stenoses (AEETES). , 2013, Journal of interventional cardiology.

[4]  Y. Ikari,et al.  Long-term efficacy of sirolimus-eluting stent for small vessel disease--subanalysis of Cypher Stent Japan Post-Marketing Surveillance Registry. , 2013, Journal of cardiology.

[5]  A. Kastrati,et al.  Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. , 2012, International journal of cardiology.

[6]  W. Wijns,et al.  Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. , 2011, American heart journal.

[7]  P. Serruys,et al.  Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everol , 2011, JACC. Cardiovascular interventions.

[8]  G. Stone,et al.  Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. , 2011, Journal of interventional cardiology.

[9]  Patrick W Serruys,et al.  An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials , 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[10]  G. Stone,et al.  Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. , 2009, American heart journal.

[11]  A. Colombo,et al.  Long-Term Follow-Up on a Large Cohort of “Full-Metal Jacket” Percutaneous Coronary Intervention Procedures , 2009, Circulation. Cardiovascular interventions.

[12]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[13]  Seung‐Jung Park,et al.  Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. , 2006, The American journal of cardiology.

[14]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.

[15]  J. Hermiller.  Contemporary treatment of small-vessel disease. , 2004, The Journal of invasive cardiology.

[16]  M Soledad Cepeda,et al.  Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. , 2003, American journal of epidemiology.

[17]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.